Skip to main content
The FDA declined to approve one of biotech’s most closely watched cancer drugs

The FDA declined to approve one of biotech’s most closely watched cancer drugs

MarketWatch.com - Top Stories
16 lis 2026, 13:07Marketwatch
Oryginał
1 min read

The FDA declined to approve one of biotech's most closely watched cancer drugs, Summit Therapeutics' lung-cancer treatment.

The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.

Z.ai
Article written by AI
Z.ai GLM-4.5-FlashFree
Free AI articles150 of 150
No limit after signing in with Telegram